Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2.6M | $33.5M |
| Cost of revenue | $0 | $0 | $0 | $204.0K | $190.0K |
| Gross profit | $0 | $0 | $0 | $2.4M | $33.3M |
| Gross margin | — | — | — | 92.3% | 99.4% |
| R&D | $0 | $0 | $0 | $42.8M | $58.2M |
| Operating income | −$173.5K | −$394.8K | −$3.1M | −$64.3M | −$51.8M |
| EBITDA | −$173.5K | −$378.8K | −$2.7M | $308.0K | −$51.8M |
| Net income | −$173.5K | −$362.8K | −$2.4M | −$61.0M | −$53.0M |
| Net margin | — | — | — | -2313.3% | -158.2% |
| EPS (diluted) | -0.01 | -0.02 | -0.15 | -1.66 | -1.11 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds HSAQ.
No tracked institution reports a position in HSAQ as of their last filing.
No one on the platform has traded HSAQ yet.
| +0.10% |
| $143M |
| — |
| LVACLAVA Medtech Acquisition Corp. | $10.43 | +0.00% | $150M | — |
| RENECartesian Growth Corporation II | $11.75 | +0.00% | $155M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.